Effect of lutein and antioxidant dietary supplementation on contrast sensitivity in age-related macular disease:A randomized controlled trial

Objective: The aim of the study is to determine the effect of lutein combined with vitamin and mineral supplementation on contrast sensitivity in people with age-related macular disease (ARMD). Design: A prospective, 9-month, double-masked randomized controlled trial. Setting: Aston University, Birmingham, UK and a UK optometric clinical practice. Subjects: Age-related maculopathy (ARM) and atrophic age-related macular degeneration (AMD) participants were randomized (using a random number generator) to either placebo (n = 10) or active (n=15) groups. Three of the placebo group and two of the active group dropped out. Interventions: The active group supplemented daily with 6 mg lutein combined with vitamins and minerals. The outcome measure was contrast sensitivity (CS) measured using the Pelli-Robson chart, for which the study had 80% power at the 5% significance level to detect a change of 0.3log units. Results: The CS score increased by 0.07 ± 0.07 and decreased by 0.02 ± 0.18 log units for the placebo and active groups, respectively. The difference between these values is not statistically significant (z = 0.903, P = 0.376). Conclusion: The results suggest that 6 mg of lutein supplementation in combination with other antioxidants is not beneficial for this group. Further work is required to establish optimum dosage levels

An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics

For a decade, The Cancer Genome Atlas (TCGA) program collected clinicopathologic annotation data along with multi-platform molecular profiles of more than 11,000 human tumors across 33 different cancer types. TCGA clinical data contain key features representing the democratized nature of the data collection process. To ensure proper use of this large clinical dataset associated with genomic features, we developed a standardized dataset named the TCGA Pan-Cancer Clinical Data Resource (TCGA-CDR), which includes four major clinical outcome endpoints. In addition to detailing major challenges and statistical limitations encountered during the effort of integrating the acquired clinical data, we present a summary that includes endpoint usage recommendations for each cancer type. These TCGA-CDR findings appear to be consistent with cancer genomics studies independent of the TCGA effort and provide opportunities for investigating cancer biology using clinical correlates at an unprecedented scale. Analysis of clinicopathologic annotations for over 11,000 cancer patients in the TCGA program leads to the generation of TCGA Clinical Data Resource, which provides recommendations of clinical outcome endpoint usage for 33 cancer types

New Fragment Separation Technology for Superheavy Element Research

This project consisted of three major research areas: (1) development of a solid Pu ceramic target for the MASHA separator, (2) chemical separation of nuclear decay products, and (3) production of new isotopes and elements through nuclear reactions. There have been 16 publications as a result of this project, and this collection of papers summarizes our accomplishments in each of the three areas of research listed above. The MASHA (Mass Analyzer for Super-Heavy Atoms) separator is being constructed at the U400 Cyclotron at the Flerov Laboratory of Nuclear Reactions in Dubna, Russia. The purpose of the separator is to physically separate the products from nuclear reactions based on their isotopic masses rather than their decay characteristics. The separator was designed to have a separation between isotopic masses of {+-}0.25 amu, which would enable the mass of element 114 isotopes to be measured with outstanding resolution, thereby confirming their discovery. In order to increase the production rate of element 114 nuclides produced via the {sup 244}Pu+{sup 48}Ca reaction, a new target technology was required. Instead of a traditional thin actinide target, the MASHA separator required a thick, ceramic-based Pu target that was thick enough to increase element 114 production while still being porous enough to allow reaction products to migrate out of the target and travel through the separator to the detector array located at the back end. In collaboration with UNLV, we began work on development of the Pu target for MASHA. Using waste-form synthesis technology, we began by creating zirconia-based matrices that would form a ceramic with plutonium oxide. We used samarium oxide as a surrogate for Pu and created ceramics that had varying amounts of the starting materials in order to establish trends in material density and porosity. The results from this work are described in more detail in Refs. [1,4,10]. Unfortunately, work on MASHA was delayed in Russia because it was found that the efficiency of transporting products from the target chamber to the detector array was much too low for applications in heavy element experiments where production rates are on the order of one atom per day or less. Work continues on the MASHA separator, and once the efficiency has been improved, we plan to continue our work on the Pu target for future element 114 experiments. Due to the delays of the MASHA separator, work on establishing the identity of heavy element species produced through nuclear reactions focused instead on chemical separations. In particular, element 115 decays through a series of alpha decays, terminating with an element 105 isotope with a long half-life ({approx} 1 day). By chemically separating the element 105 daughter and observing its subsequent fission decay, the identity of the original parent nucleus can be established through the genetic correlation of the initial series of alpha decays. Chemical separations of element 105 were developed in Switzerland, Russia, and at LLNL. Over the course of two experiments, reaction products from the {sup 243}Am+{sup 48}Ca reaction were collected in a copper block and subsequently processed for chemical separation of the Group Five elements [8,9,13,15]. The Group Five elements were initially separated from the Group Four species, and then the samples were sub-divided into tantalum and niobium fractions. All of the fission events were observed in the tantalum fractions, which implied that element 105 behaved more like tantalum under the chemical conditions of these experiments. These experiments were very successful, and not only demonstrated that chemical separation could be performed on single atoms of interest, but also lent proof to the identity of the parent nucleus as element 115. Subsequent analysis of the alpha spectra taken during the experiment further prove that the fission events observed during the two experiments came from element 105 as the decay daughter of element 115 and could not attributed to interference from other background species [16]. The final aspect of this project was the production of new isotopes and elements. All of the experiments were performed in Dubna at the U400 Cyclotron and the results are described in more detail in Refs. [2,3,5-8,11,12,14]. The first experiments were designed to establish the decay properties of isotopes of elements 112, 114, and 116 [5]. Because these isotopic signatures were established through these initial experiments, the discovery of element 118 [11] was possible, since the 118 nuclides decayed into these previously studied isotopes. This was the first successful report of the discovery of element 118, which was reported by the media to a large extent. The last experiment that was performed for this project was the production and detection of a new isotope of element 113 [14]

Cloning and Characterization of Genes Involved in Nostoxanthin Biosynthesis of Sphingomonas elodea ATCC 31461

Most Sphingomonas species synthesize the yellow carotenoid nostoxanthin. However, the carotenoid biosynthetic pathway of these species remains unclear. In this study, we cloned and characterized a carotenoid biosynthesis gene cluster containing four carotenogenic genes (crtG, crtY, crtI and crtB) and a β-carotene hydroxylase gene (crtZ) located outside the cluster, from the gellan-gum producing bacterium Sphingomonas elodea ATCC 31461. Each of these genes was inactivated, and the biochemical function of each gene was confirmed based on chromatographic and spectroscopic analysis of the intermediates accumulated in the knockout mutants. Moreover, the crtG gene encoding the 2,2′-β-hydroxylase and the crtZ gene encoding the β-carotene hydroxylase, both responsible for hydroxylation of β-carotene, were confirmed by complementation studies using Escherichia coli producing different carotenoids. Expression of crtG in zeaxanthin and β-carotene accumulating E. coli cells resulted in the formation of nostoxanthin and 2,2′-dihydroxy-β-carotene, respectively. Based on these results, a biochemical pathway for synthesis of nostoxanthin in S. elodea ATCC 31461 is proposed

Rare disruptive mutations in ciliary function genes contribute to testicular cancer susceptibility

Testicular germ cell tumour (TGCT) is the most common cancer in young men. Here we sought to identify risk factors for TGCT by performing whole-exome sequencing on 328 TGCT cases from 153 families, 634 sporadic TGCT cases and 1,644 controls. We search for genes that are recurrently affected by rare variants (minor allele frequency <0.01) with potentially damaging effects and evidence of segregation in families. A total of 8.7% of TGCT families carry rare disruptive mutations in the cilia-microtubule genes (CMG) as compared with 0.5% of controls (P=2.1 × 10¯⁸). The most significantly mutated CMG is DNAAF1 with biallelic inactivation and loss of DNAAF1 expression shown in tumours from carriers. DNAAF1 mutation as a cause of TGCT is supported by a dnaaf1hu²⁵⁵h(+/−) zebrafish model, which has a 94% risk of TGCT. Our data implicate cilia-microtubule inactivation as a cause of TGCT and provide evidence for CMGs as cancer susceptibility genes

Macular and serum carotenoid concentrations in patients with malabsorption syndromes

The carotenoids lutein and zeaxanthin are believed to protect the human macula by absorbing blue light and quenching free radicals. Intestinal malabsorption syndromes such as celiac and Crohn’s disease are known to cause deficiencies of lipid-soluble nutrients. We hypothesized that subjects with nutrient malabsorption syndromes will demonstrate lower carotenoid levels in the macula and blood, and that these lower levels may correlate with early-onset maculopathy. Resonance Raman spectrographic (RRS) measurements of macular carotenoid levels were collected from subjects with and without a history of malabsorption syndromes. Carotenoids were extracted from serum and analyzed by high performance liquid chromatography (HPLC). Subjects with malabsorption (n = 22) had 37% lower levels of macular carotenoids on average versus controls (n = 25, P < 0.001). Malabsorption was not associated with decreased serum carotenoid levels. Convincing signs of early maculopathy were not observed. We conclude that intestinal malabsorption results in lower macular carotenoid levels

Declining mortality following acute myocardial infarction in the Department of Veterans Affairs Health Care System

<p>Abstract</p> <p>Background</p> <p>Mortality from acute myocardial infarction (AMI) is declining worldwide. We sought to determine if mortality in the Veterans Health Administration (VHA) has also been declining.</p> <p>Methods</p> <p>We calculated 30-day mortality rates between 2004 and 2006 using data from the VHA External Peer Review Program (EPRP), which entails detailed abstraction of records of all patients with AMI. To compare trends within VHA with other systems of care, we estimated relative mortality rates between 2000 and 2005 for all males 65 years and older with a primary diagnosis of AMI using administrative data from the VHA Patient Treatment File and the Medicare Provider Analysis and Review (MedPAR) files.</p> <p>Results</p> <p>Using EPRP data on 11,609 patients, we observed a statistically significant decline in adjusted 30-day mortality following AMI in VHA from 16.3% in 2004 to 13.9% in 2006, a relative decrease of 15% and a decrease in the odds of dying of 10% per year (p = .011). Similar declines were found for in-hospital and 90-day mortality.</p> <p>Based on administrative data on 27,494 VHA patients age 65 years and older and 789,400 Medicare patients, 30-day mortality following AMI declined from 16.0% during 2000-2001 to 15.7% during 2004-June 2005 in VHA and from 16.7% to 15.5% in private sector hospitals. After adjusting for patient characteristics and hospital effects, the overall relative odds of death were similar for VHA and Medicare (odds ratio 1.02, 95% C.I. 0.96-1.08).</p> <p>Conclusion</p> <p>Mortality following AMI within VHA has declined significantly since 2003 at a rate that parallels that in Medicare-funded hospitals.</p